<PAGE>
OMB APPROVAL
OMB Number:3235-0145
Expires: August 31, 1999
Estimated average burden
hours per form 14.90
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. *)
Immulogic Pharmaceutical Corporation
(Name of Issuer)
Common Stock
(Title of Class of Securities)
45252R100
(CUSIP Number)
November 12, 1998
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
/ XX / Rule 13d-1(b)
/___/ Rule 13d-1(c)
/___/ Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of the
Act (however, see the Notes).
Potential persons who are to respond to the collection of information
contained in this form are not required to respond unless the form displays
a currently valid OMB control number.
SEC 1745 (3-98) Page 1 of *
<PAGE>
CUSIP No. 45252R100 Page 2 of 6 Pages
- ----------------------------------------------------------------
1 NAME OF REPORTING PERSONS
IRS IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Kenneth Luskin, doing business as Intrinsic Value Asset Management
- ----------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions)
(a)/ /
(b)/XX/
- ----------------------------------------------------------------
3 SEC USE ONLY
- ----------------------------------------------------------------
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
- ----------------------------------------------------------------
NUMBER OF 5 SOLE VOTING POWER
SHARES 6,500
BENEFICIALLY ---------------------------------------
OWNED BY 6 SHARED VOTING POWER
EACH 1,077,500
REPORTING ---------------------------------------
PERSON 7 SOLE DISPOSITIVE POWER
WITH 6,500
---------------------------------------
8 SHARED DISPOSITIVE POWER
1,077,500
- ----------------------------------------------------------------
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,084,000
- ----------------------------------------------------------------
10 CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (See
Instructions)
- ----------------------------------------------------------------
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
5.3%
- ----------------------------------------------------------------
12 TYPE OF REPORTING PERSON (See Instructions)
IA
- ----------------------------------------------------------------
<PAGE>
CUSIP No. 45252R100 13G Page 3 of 6 Pages
ITEM 1.
(a) The name of the issuer is Immulogic Pharmaceutical Corporation
(the "Issuer").
(b) The principal executive office of the Issuer is located at
610 Lincoln Street, Waltham, MA 02451.
ITEM 2.
(a) The name of the person filing this statement is Kenneth Luskin,
doing business as Intrinsic Value Asset Management (the "Filer").
(b) The principal business office of the Filer is located at 24955
Pacific Coast Highway, Suite C-204, Malibu, CA 90265.
(c) See Item 4 of the cover sheet for the Filer.
(d) This statement relates to shares of common stock of the Issuer
(the "Stock").
(e) The CUSIP number of the Stock is 45252R100.
<PAGE>
CUSIP No. 45252R100 13G Page 4 of 6 Pages
ITEM 3. If this statement is filed pursuant to rule 240.13d-1(b) or
240.13d-2(b) or (c), check whether the person filing is a:
(a) ___ Broker or dealer registered under section 15 of the Act (15
U.S.C. 78o).
(b) ___ Bank as defined in section 3(a)(6) of the Act (15 U.S.C.
78c).
(c) ___ Insurance company as defined in section 3(a)(19) of the Act
(15 U.S.C. 78c).
(d) ___ Investment company registered under section 8 of the
Investment Company Act of 1940 (15 U.S.C. 80a-8).
(e) XX An investment adviser in accordance with 240.13d-
1(b)(1)(ii)(E).
(f) ___ An employee benefit plan or endowment fund in accordance
with 240.13d-1(b)(1)(ii)(F).
(g) ___ A parent holding company or control person in accordance
with 240.13d-1(b)(1)(ii)(G)
(h) ___ A savings association as defined in section 3(b) of the
Federal Deposit Insurance Act (12 U.S.C. 1813).
(i) ___ A church plan that is excluded from the definition of an
investment company under section 3(c)(14) of the Investment Company Act of
1940 (15 U.S.C. 80a-3).
(j) ___ Group, in accordance with section 240.13d-1(b)(1)(ii)(J)
<PAGE>
CUSIP No. 45252R100 13G Page 5 of 6 Pages
ITEM 4. OWNERSHIP
See Items 5-9 and 11 on the cover sheet for the Filer.
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS
If this statement is being filed to report the fact that as of the date
hereof the reporting person has ceased to be the beneficial owner of more
than five percent of the class of securities, check the following /___/.
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON
Kenneth Luskin is an investment adviser registered with the State of
California whose clients have the right to receive or the power to direct
the receipt of dividends from, or the proceeds from the sale of, the Stock.
No individual client's holdings of the Stock are more than five percent of
the class.
<PAGE>
CUSIP No. 45252R100 13G Page 6 of 6 Pages
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED
THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY
Not applicable.
ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP
Not applicable.
ITEM 9. NOTICE OF DISSOLUTION OF GROUP
Not applicable.
By signing below I certify that, to the best of my knowledge and belief,
the securities referred to above were acquired and are held in the ordinary
course of business and were not acquired and are not held for the purpose
of or with the effect of changing or influencing the control of the Issuer
of the securities and were not acquired are not held in connection with or
as a participant in any transaction having that purpose or effect.
Dated: November 12, 1998
/s/ Kenneth Luskin_____________________
Kenneth Luskin
